Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 4/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 15/20 | 0.67 |
| ▸ | ATF1 | P18846 | 14/20 | 0.67 |
| ▸ | JUN | P05412 | 2/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.61 |
| ▸ | RELA | Q04206 | 2/20 | 0.61 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1862523 | 0.86 | NFKB1 (0.74) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL1864557 | 0.84 | NFKB1 (0.78) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL13077672 | 0.81 | XPO1 (0.71) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL17448384 | 0.77 | P2RX1 (0.63) | P2RX1 | |
| SCHEMBL458841 | 0.77 | NFKB1 (1.00) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL13189703 | 0.75 | P2RX1 (1.00) | P2RX1 | |
| SCHEMBL2532524 | 0.74 | GRM4 (0.74) | P2RX1 | |
| SCHEMBL23309615 | 0.73 | P2RX1 (0.58) | P2RX1 | |
| SCHEMBL8406630 | 0.73 | P2RX1 (0.75) | P2RX1 | |
| SCHEMBL17531734 | 0.73 | P2RX1 (0.64) | P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280036-A1 | Modulation of Pathogenicity | NR4A1, NR4A2, NR4A3 | XPO1 1607/4885NFKB1 2117/4885ATF1 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.